What is the role of adipokines in myasthenia gravis?
Authors Rozmilowska I, Czyzewski D, Mazur B, Adamczyk-Sowa M
Received 28 January 2018
Accepted for publication 3 April 2018
Published 28 August 2018 Volume 2018:14 Pages 1515—1525
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Garry Walsh
Izabela Rozmilowska,1 Damian Czyzewski,2 Bogdan Mazur,3 Monika Adamczyk-Sowa1
1Department of Neurology, Medical University of Silesia, Zabrze, Poland; 2Department of Thoracic Surgery, Medical University of Silesia, Zabrze, Poland; 3Department of Microbiology, Medical University of Silesia, Zabrze, Poland
Objective: Myasthenia gravis (MG) is a disease with autoimmune etiology. The main pathomechanism is related to the production of antibodies against nicotinic acetylcholine receptor. The present study is aimed to compare the serum level of adipokines in patients with MG with that in controls, as well as to study the relation of these levels with disease severity.
Patients and methods: Fifty patients with MG and 30 healthy individuals were enrolled in our study. Serum concentrations of select adipokines, namely adiponectin, leptin, omentin, visfatin, and resistin were measured.
Results: The results showed a significant increase in serum concentrations of adiponectin and resistin in the patients with MG compared with the controls.
Conclusion: Further studies are warranted to assess changes in adipokine concentration levels in patients with MG.
Keywords: adiponectin, leptin, resistin, visfatin, omentin
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]